Thorotrast is a radioactive radiographic contrast agent containing thorium dioxide first produced in Germany in 1928 and was in use until the 1950s. It was used primarily for cerebral angiography, and 90% of the estimated 50,000-100,000 patients who received it were studied for this purpose.
The deposition of Thorotrast is dependant on its radiological use, preparation method, and the age of the preparation; however, the primary site is the reticuloendothelial system such as liver, spleen, bone marrow, lymph nodes. A plain radiograph of the abdomen demonstrates fine, irregular metallic densities distributed throughout the liver, spleen and parapancreatic lymph nodes 4.
Thorotrast is carcinogenic with hepatic angiosarcomas being the classical thorotrast-related neoplasm. Other thorotrast-related neoplasms include:
- 1. Bohatirchuk FP, Jeletzky TF, Ivan LP. Contact historadiography of nervous tissue impregnated with thorotrast. Am J Roentgenol Radium Ther Nucl Med. 1973;118 (4): 923-6. - Pubmed citation
- 2. Tondreau RL. The retrospectoscope. Egas Moniz 1874-1955. Radiographics. 1985;5 (6): 994-7. Radiographics (citation) - Pubmed citation
- 3. Stover BJ. Effects of Thorotrast in humans. Health Phys. 1983;44 Suppl 1 : 253-7. - Pubmed citation
- 4. Weber E, Laarbaui F, Michel L et-al. Abdominal pain: do not forget Thorotrast!. Postgrad Med J. 1995;71 (836): 367-8. doi:10.1136/pgmj.71.836.367 - Free text at pubmed - Pubmed citation